People needs to have thoroughly recovered with the acute poisonous outcomes of all prior anti-cancer therapy and will have to satisfy the subsequent minimum amount duration from prior anti-most cancers directed therapy prior to enrollment. Experimental: Dose expansion_sub-population 2_higher dose of niraparib MTDs and/or applicant RP2Ds for elimusertib utilised together https://dukel776zlw9.blogaritma.com/profile